Please provide your email address to receive an email when new articles are posted on . A 2.5 mg/mL dose of triamcinolone acetonide showed equally as efficacious treatment for nail psoriasis vs.

First patient enrolled in Phase 3 hip OA registration trial in late December 2018; trial expected to complete in 2020 Positive results from Phase 2 pharmacokinetics (PK) study of ZILRETTA in OA of ...

To report on the follow-up of patients who received an intravitreal triamcinolone acetonide injection (IVTA) as treatment of exudative age-related macular degeneration. The prospective interventional ...

Evaluation concluded that ZILRETTA provided effective pain relief, was generally well-tolerated, and expands the treatment options available for the management of osteoarthritis knee pain ...

Hikma is offering triamcinolone acetonide injectable suspension in a 40mg/ml dose. The product is indicated for various inflammatory, autoimmune, hormonal and other conditions where a corticosteroid ...

BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy ...

Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — A single subconjunctival 4 mg triamcinolone injection after retinal surgery had ...

sNDA aims to revise the product label with new data indicating repeat administration of ZILRETTA was safe and well tolerated BURLINGTON, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, ...

Amneal's triamcinolone acetonide is currently the only AP-rated generic equivalent injectable suspension available. Amneal Biosciences has received approval from the Food and Drug Administration (FDA) ...

May 7, 2003 — Intravitreal injection of triamcinolone is helpful in patients with refractory diabetic macular edema, according to a presentation on May 7 at the Association for Research in Vision and ...

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced ...